Retatrutide vs Tirzepatide: Complete Comparison

Side-by-Side Comparison

The 6.2 Percentage Point Gap: Does It Matter?

At first glance, a difference of 28.7% vs 22.5% may seem modest. But in practice, the real-world significance is considerable:

• For a 250 lb (113 kg) person: 28.7% = ~72 lbs lost vs 22.5% = ~56 lbs lost — a 16 lb difference
• More patients on retatrutide would achieve >25% body weight loss — a threshold associated with substantial improvements in cardiovascular, metabolic, and musculoskeletal outcomes
• The "super-responder" tail (patients losing 30–40%+ of body weight) appears larger with retatrutide based on Phase 2 distribution data

Important caveat: TRIUMPH-4 (retatrutide, obesity + knee OA, NCT05931367) and SURMOUNT-1 (tirzepatide) enrolled different populations with different inclusion criteria. TRIUMPH-4 included patients with knee osteoarthritis; SURMOUNT-1 enrolled people with obesity without T2D. Direct head-to-head comparison has not been conducted.

Mechanism: Why Triple Beats Dual

Tirzepatide's GIP/GLP-1 dual agonism was itself a major advance over single GLP-1 agonists. The addition of a glucagon receptor component in retatrutide adds two key mechanisms:

• Enhanced hepatic fat oxidation: Glucagon receptor activation drives the liver to burn more fatty acids, reducing hepatic steatosis and supporting metabolic normalization
• Increased basal energy expenditure: Glucagon increases thermogenesis and resting metabolic rate, complementing the appetite suppression from GLP-1

Tirzepatide cannot directly activate glucagon receptors. This appears to explain why, even at its maximum dose of 15 mg, its efficacy ceiling is lower than retatrutide's.

Expected Pricing and Availability

Tirzepatide (Zepbound) is available now at approximately $1,086/month list price, or $299–$449/month through LillyDirect self-pay vials, with savings cards bringing costs as low as $25/month for commercially insured patients.

Retatrutide is not yet FDA-approved and has no announced pricing. Projected launch: NDA submission Q4 2026, approval no earlier than late 2027, first prescriptions Q1–Q2 2028 at earliest. See the TRIUMPH trial tracker for current timelines.

Mechanism Deep-Dive: Why Triple > Dual Agonism

GLP-1 receptor agonism drives appetite suppression in all drugs in this class. GIP co-agonism (tirzepatide's addition over semaglutide) adds CNS food-intake reduction and buffers GI side effects—allowing higher effective GLP-1 engagement. The result: tirzepatide roughly doubled average weight loss versus semaglutide in SURPASS trials.

The glucagon receptor (GcgR) component is retatrutide's key addition. According to Knerr et al. in Molecular Metabolism (2022), concurrent GLP-1/GIP/glucagon activation “combines the anorectic and insulinotropic activities of GLP-1 and GIP with the energy expenditure effect of glucagon.” In preclinical comparisons, triple agonists produced more weight loss than tirzepatide despite similar food intake suppression—the extra loss came entirely from increased resting energy expenditure. The authors concluded: “the potency of GcgR agonism defines the maximal weight-lowering capacity of the triple agonist.”

In plain terms: tirzepatide reduces how much you eat. Retatrutide reduces how much you eat and raises how many calories you burn at rest. One trade-off: glucagon is chronotropic, producing a heart rate increase not seen with tirzepatide.

TRIUMPH-1 Phase 2 NEJM Results

The Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.) enrolled 338 adults with obesity or overweight without type 2 diabetes, randomized to retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg weekly versus placebo over 48 weeks. The dose-response data were striking:

At 12 mg (48 weeks): 100% lost ≥5%, 93% lost ≥10%, 83% lost ≥15%, and 26% lost ≥30%—a threshold associated with bariatric surgery outcomes. Trial completion was 81%; discontinuation due to adverse events ranged 6–16% across dose groups.

TRIUMPH-1 Phase 3 Topline Results (May 2026)

On May 21, 2026, Eli Lilly announced positive topline results from TRIUMPH-1 in 2,339 adults with obesity or overweight and no type 2 diabetes. The 12 mg dose produced 28.3% mean weight loss at 80 weeks (~70.3 lbs) versus 2.2% on placebo. All primary and key secondary endpoints were met at all three doses. Key thresholds at 12 mg:

• 62.5% achieved ≥25% weight loss; 45.3% achieved ≥30%
• 27.2% achieved ≥35% weight loss; 65.3% exited the obesity classification

A prespecified 104-week extension (BMI ≥35 subgroup) reached 30.3% mean weight loss with no plateau through two years—a distinction from tirzepatide, which showed a plateau around weeks 52–60 in SURMOUNT-1. These data are from Eli Lilly's May 21, 2026 press release; peer-reviewed publication was pending at the time of this update.

Side Effect Profile: Glucagon's Cost

Both drugs share the GLP-1 GI profile (nausea, vomiting, diarrhea, constipation), but rates differ. Nausea: ~43% with retatrutide 12 mg (TRIUMPH-4 Phase 3) vs. 31% with tirzepatide 15 mg (SURMOUNT-1). Discontinuation due to adverse events: 11.3% in TRIUMPH-1 (down from 18.2% in TRIUMPH-4 via optimized titration) vs. 4.3–7.1% for tirzepatide—still roughly twice the rate.

Glucagon adds two signals absent with tirzepatide: (1) a heart rate increase of +5–8 bpm at 12 mg (tirzepatide: +1–3 bpm), under long-term cardiovascular assessment in TRIUMPH-Outcomes (NCT06383390, results 2028–2029); and (2) dysesthesia—abnormal skin sensations—in approximately 20.9% of highest-dose TRIUMPH-4 participants, not observed with tirzepatide. The ~5–6 percentage point extra weight loss may justify these trade-offs for many patients; that decision belongs with the prescribing clinician.

FDA Approval Pipeline & Timeline

Retatrutide is not FDA-approved as of June 2026 and is available only in clinical trials. Based on TRIUMPH-1 data (May 2026), the projected milestones are: NDA submission Q4 2026 → FDA acceptance Q1 2027 → advisory committee mid-2027 → approval decision late 2027 (priority review) or early 2028 (standard review) → first prescriptions Q1–Q2 2028 at earliest. Lilly plans to submit for obesity, knee osteoarthritis, and obstructive sleep apnea indications. Priority review designation has not been confirmed. Remaining trials TRIUMPH-2 (T2D, results Q3–Q4 2026), TRIUMPH-3 (CV disease, late 2026/early 2027), and TRIUMPH-5 (weight maintenance) are ongoing and will support the NDA package. See RetaWeightLoss.com's June 2026 update for latest tracking.

Cost Projections at Launch

Retatrutide has no FDA approval, no National Drug Code, and no payer contracts as of June 2026—no pricing exists. Based on Lilly's tirzepatide precedent, analysts project a list price (WAC) of $1,000–$1,500/month, a LillyDirect self-pay pathway of $400–$600/month, and a commercial insurance savings card bringing costs to ~$25–$50/month for eligible patients. Medicare coverage is unlikely before 2029–2030. According to GLP-1 Clinics' pre-launch cost analysis, broad coverage will not arrive until at least 2029–2030, with early access through out-of-pocket or manufacturer direct programs. These are projections only, not official Lilly guidance. Any vendor claiming to sell retatrutide before FDA approval is offering an unapproved and unregulated substance.

Which Should You Choose?

Updated Head-to-Head Comparison

Cross-trial comparison only. No direct head-to-head RCT between retatrutide and tirzepatide has been conducted. Population characteristics and trial durations differ.